Literature DB >> 29973687

TR4 nuclear receptor promotes clear cell renal cell carcinoma (ccRCC) vasculogenic mimicry (VM) formation and metastasis via altering the miR490-3p/vimentin signals.

Jian Bai1,2, Shuyuan Yeh2, Xiaofu Qiu1,2, Linyi Hu2, Jun Zeng1, Yangke Cai1, Li Zuo1,3, Gonghui Li2, Guosheng Yang4, Chawnshang Chang5,6.   

Abstract

While TR4 nuclear receptor plays key roles to promote prostate cancer progression, its roles to alter the progression of clear cell renal cell carcinoma (ccRCC), remains unclear. Here, we demonstrate that TR4 can promote the ccRCC cell vasculogenic mimicry (VM) formation and its associated metastasis via modulating the miR490-3p/vimentin (VIM) signals. Mechanism dissection revealed that TR4 might increase the oncogene VIM expression via decreasing the miR-490-3p expression through direct binding to the TR4-response-elements (TR4REs) on the promoter region of miR-490-3p, which might then directly target the 3' UTR of VIM-mRNA to increase its protein expression. Preclinical studies using the in vivo mouse model with xenografted RCC Caki-1 cells into the sub-renal capsule of nude mice also found that TR4 could promote the ccRCC VM and its associated metastasis via modulating the miR490-3p/VIM signals. Together, results from preclinical studies using multiple RCC cell lines and the in vivo mouse model all conclude that TR4 may play a key role to promote ccRCC VM formation and metastasis and targeting the newly identified TR4/miR-490-3p/VIM signals with small molecules may help us to develop a new therapeutic approach to better suppress the ccRCC metastasis.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29973687     DOI: 10.1038/s41388-018-0269-1

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  46 in total

1.  Clinical significance of vimentin-positive gastric cancer cells.

Authors:  Yuhiko Fuyuhiro; Masakazu Yashiro; Satoru Noda; Shinichiro Kashiwagi; Junko Matsuoka; Yosuke Doi; Yukihiro Kato; Naoshi Kubo; Masaichi Ohira; Kosei Hirakawa
Journal:  Anticancer Res       Date:  2010-12       Impact factor: 2.480

2.  TR4 activates FATP1 gene expression to promote lipid accumulation in 3T3-L1 adipocytes.

Authors:  Hojung Choi; Seung-Jin Kim; Sung-Soo Park; Chawnshang Chang; Eungseok Kim
Journal:  FEBS Lett       Date:  2011-08-11       Impact factor: 4.124

Review 3.  Tumour stem cells and drug resistance.

Authors:  Michael Dean; Tito Fojo; Susan Bates
Journal:  Nat Rev Cancer       Date:  2005-04       Impact factor: 60.716

4.  TR4 nuclear receptor functions as a tumor suppressor for prostate tumorigenesis via modulation of DNA damage/repair system.

Authors:  Shin-Jen Lin; Soo Ok Lee; Yi-Fen Lee; Hiroshi Miyamoto; Dong-Rong Yang; Gonghui Li; Chawnshang Chang
Journal:  Carcinogenesis       Date:  2014-02-28       Impact factor: 4.944

5.  MicroRNA-218 inhibits cell migration and invasion in renal cell carcinoma through targeting caveolin-2 involved in focal adhesion pathway.

Authors:  Takeshi Yamasaki; Naohiko Seki; Hirofumi Yoshino; Toshihiko Itesako; Hideo Hidaka; Yasutoshi Yamada; Shuichi Tatarano; Tomokazu Yonezawa; Takashi Kinoshita; Masayuki Nakagawa; Hideki Enokida
Journal:  J Urol       Date:  2013-02-27       Impact factor: 7.450

6.  Growth retardation and abnormal maternal behavior in mice lacking testicular orphan nuclear receptor 4.

Authors:  Loretta L Collins; Yi-Fen Lee; Cynthia A Heinlein; Ning-Chun Liu; Yei-Tsung Chen; Chih-Rong Shyr; Charles K Meshul; Hideo Uno; Kenneth A Platt; Chawnshang Chang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-10-11       Impact factor: 11.205

7.  Increased chemosensitivity via targeting testicular nuclear receptor 4 (TR4)-Oct4-interleukin 1 receptor antagonist (IL1Ra) axis in prostate cancer CD133+ stem/progenitor cells to battle prostate cancer.

Authors:  Dong-Rong Yang; Xian-Fan Ding; Jie Luo; Yu-Xi Shan; Ronghao Wang; Shin-Jen Lin; Gonghui Li; Chiung-Kuei Huang; Jin Zhu; Yuhchyau Chen; Soo Ok Lee; Chawnshang Chang
Journal:  J Biol Chem       Date:  2013-04-22       Impact factor: 5.157

8.  Transactivation of vimentin by beta-catenin in human breast cancer cells.

Authors:  Christine Gilles; Myriam Polette; Mélanie Mestdagt; Béatrice Nawrocki-Raby; Philippe Ruggeri; Philippe Birembaut; Jean-Michel Foidart
Journal:  Cancer Res       Date:  2003-05-15       Impact factor: 12.701

9.  Human and rat TR4 orphan receptors specify a subclass of the steroid receptor superfamily.

Authors:  C Chang; S L Da Silva; R Ideta; Y Lee; S Yeh; J P Burbach
Journal:  Proc Natl Acad Sci U S A       Date:  1994-06-21       Impact factor: 11.205

10.  Reduced osteoblast activity in the mice lacking TR4 nuclear receptor leads to osteoporosis.

Authors:  Shin-Jen Lin; Hsin-Chiu Ho; Yi-Fen Lee; Ning-Chun Liu; Su Liu; Gonghui Li; Chih-Rong Shyr; Chawnshang Chang
Journal:  Reprod Biol Endocrinol       Date:  2012-06-07       Impact factor: 5.211

View more
  18 in total

1.  LncRNA n339260 functions in hepatocellular carcinoma progression via regulation of miRNA30e-5p/TP53INP1 expression.

Authors:  Tieju Liu; Jing Mo; Shihan Liao; Xiaoyu Bai; Yanlei Li; Yanhui Zhang; Danfang Zhang; Runfen Cheng; Nan Zhao; Na Che; Yuhong Guo; Xueyi Dong; Xiulan Zhao
Journal:  J Gastroenterol       Date:  2022-07-08       Impact factor: 6.772

Review 2.  A Review of Recent Research on the Role of MicroRNAs in Renal Cancer.

Authors:  Longfei Yang; Xiaofeng Zou; Junrong Zou; Guoxi Zhang
Journal:  Med Sci Monit       Date:  2021-05-08

3.  Akirin2 is modulated by miR-490-3p and facilitates angiogenesis in cholangiocarcinoma through the IL-6/STAT3/VEGFA signaling pathway.

Authors:  Kaiming Leng; Yi Xu; Pengcheng Kang; Wei Qin; Hailong Cai; Hao Wang; Daolin Ji; Xingming Jiang; Jinglin Li; Zhenglong Li; Lining Huang; Xiangyu Zhong; Xueying Sun; Zhidong Wang; Yunfu Cui
Journal:  Cell Death Dis       Date:  2019-03-18       Impact factor: 8.469

4.  Hypoxia promotes vasculogenic mimicry formation by vascular endothelial growth factor A mediating epithelial-mesenchymal transition in salivary adenoid cystic carcinoma.

Authors:  Hao-Fan Wang; Sha-Sha Wang; Min Zheng; Lu-Ling Dai; Ke Wang; Xiao-Lei Gao; Ming-Xin Cao; Xiang-Hua Yu; Xin Pang; Mei Zhang; Jing-Biao Wu; Jia-Shun Wu; Xiao Yang; Ya-Jie Tang; Yu Chen; Ya-Ling Tang; Xin-Hua Liang
Journal:  Cell Prolif       Date:  2019-04-03       Impact factor: 6.831

5.  Targeting the ERβ/Angiopoietin-2/Tie-2 signaling-mediated angiogenesis with the FDA-approved anti-estrogen Faslodex to increase the Sunitinib sensitivity in RCC.

Authors:  Junfei Gu; Yong Zhang; Zhenwei Han; Lei Gao; Jinfeng Cui; Yin Sun; Yuanjie Niu; Bosen You; Chi-Ping Huang; Chawnshang Chang; Xiaolu Wang; Shuyuan Yeh
Journal:  Cell Death Dis       Date:  2020-05-14       Impact factor: 8.469

Review 6.  Vasculogenic mimicry in carcinogenesis and clinical applications.

Authors:  Qingxi Luo; Jun Wang; Wenyuan Zhao; Zhenzi Peng; Xianyu Liu; Bin Li; Heng Zhang; Bin Shan; Chunfang Zhang; Chaojun Duan
Journal:  J Hematol Oncol       Date:  2020-03-14       Impact factor: 17.388

Review 7.  MicroRNA-490-3p and -490-5p in carcinogenesis: Separate or the same goal?

Authors:  Yin Li; Dongmei Tian; Hao Chen; Yuanting Cai; Sang Chen; Shiwei Duan
Journal:  Oncol Lett       Date:  2021-07-22       Impact factor: 2.967

Review 8.  Advances and Prospects of Vasculogenic Mimicry in Glioma: A Potential New Therapeutic Target?

Authors:  Heng Cai; Wenjing Liu; Xiaobai Liu; Zhiqing Li; Tianda Feng; Yixue Xue; Yunhui Liu
Journal:  Onco Targets Ther       Date:  2020-05-21       Impact factor: 4.147

9.  A novel definition of microvessel density in renal cell carcinoma: Angiogenesis plus vasculogenic mimicry.

Authors:  Yanyuan Wu; Kun Du; Wenbin Guan; Di Wu; Haixiao Tang; Ning Wang; Jun Qi; Zhengqin Gu; Junyao Yang; Jie Ding
Journal:  Oncol Lett       Date:  2020-09-03       Impact factor: 2.967

10.  Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.

Authors:  Hangchuan Shi; Yin Sun; Miao He; Xiong Yang; Michiaki Hamada; Tsukasa Fukunaga; Xiaoping Zhang; Chawnshang Chang
Journal:  Oncogene       Date:  2019-09-09       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.